{"id":"d07001-softgel-capsules","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Insomnia"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This action results in increased levels of the neurotransmitter in the synaptic cleft, leading to its therapeutic effects. The exact mechanism of action is not fully understood, but it is believed to play a role in the treatment of certain conditions.","oneSentence":"D07001-Softgel Capsules is a medication that works by inhibiting the reuptake of a specific neurotransmitter.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:26.117Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT05065957","phase":"PHASE2, PHASE3","title":"Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"InnoPharmax Inc.","startDate":"2022-03-29","conditions":"Biliary Tract Cancer","enrollment":180},{"nctId":"NCT06622057","phase":"PHASE3","title":"D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"InnoPharmax Inc.","startDate":"2025-07-01","conditions":"Biliary Tract Cancer (BTC)","enrollment":195},{"nctId":"NCT03531320","phase":"PHASE1, PHASE2","title":"Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase","status":"COMPLETED","sponsor":"InnoPharmax Inc.","startDate":"2018-08-06","conditions":"Gastrointestinal Cancer, Biliary Tract Cancer","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"D07001-Softgel Capsules","genericName":"D07001-Softgel Capsules","companyName":"InnoPharmax Inc.","companyId":"innopharmax-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"D07001-Softgel Capsules are a small molecule cyclooxygenase inhibitor, classified as an INHIBITOR. They are being studied in combination with Capecitabine for the treatment of Advanced Biliary Tract Cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}